
Sonoma Pharmaceuticals, Inc.
SNOANASDAQHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$1.34
$0.00 · 0.00%
SNOA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
69
Undervalued
Momentum
31
Weakening
Sentiment
53
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSonoma Pharmaceuticals, Inc. specializes in the creation and distribution of stabilized hypochlorous acid (HOCl) products. These offerings address a diverse range of medical and health needs, including wound management, veterinary care, ocular hygiene, oral health, and various dermatological conditions. The company's market reach extends across the United States, Latin America, Europe, and other international territories. Its comprehensive product line features: Epicyn: an antimicrobial cleanser for facial use. Levicyn: a prescription HOCl-based treatment formulated to ease the burning, itching, and pain associated with numerous dermatological issues. Celacyn gel: a topical HOCl-based prescription product engineered to facilitate efficient healing and management of both new and old scars. SebuDerm: designed to soothe the burning, itching, redness, scaling, and discomfort linked to seborrhea and seborrheic dermatitis. Acuicyn: an HOCl-based solution for alleviating ocular itch and inflammation, while also maintaining cleanliness around the eyes. Microcyn: a topical HOCl product family aimed at accelerating wound healing by combating a wide spectrum of pathogens, including antibiotic-resistant strains that can impede natural recovery. MicrocynAH: an HOCl-based solution specifically for animals, providing relief for common conditions like hot spots, scratches, skin rashes, post-surgical sites, and irritated skin to support healing. Microdacyn60: an oral care solution for treating infections of the mouth and throat. MucoClyns: suitable for emergency use and safe for application on mucous membranes, cuts, abrasions, burns, and other body surfaces. Endocyn: a series of solutions for root canal irrigation. Pediacyn: a hydrogel designed for atopic dermatitis. Ocucyn: a cleanser for eyelids and eyelashes. Gramaderm: for the topical treatment of mild to moderate acne. Nanocyn: a hospital-grade disinfectant. Sinudox: for nasal irrigation purposes. Originally incorporated in 1999 as Oculus Innovative Sciences, Inc., the company officially rebranded to Sonoma Pharmaceuticals, Inc. in December 2016. Its headquarters are located in Woodstock, Georgia.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Amy Trombly
- Listed since
- Jan 25, 2007
- Employees
- 10
Market position
Day range
Current $1.34
52-week range
Current $1.34
- Open
- $1.3201
- Previous close
- $1.34
- Volume
- 66.58K
- 0.3× average
- Average volume
- 224.69K
- Average daily volume
- Market cap
- 2.26M USD
- Beta
- 1.29
- Market reference 1
- 50-day average
- $1.2118
- +10.58% above average
- 200-day average
- $2.2659
- -40.86% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -1.1×
- P/B (TTM)
- 0.78×
- P/S (TTM)
- 0.1×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 38.91%
- Operating margin
- -6.41%
- Net margin
- -10.33%
Financial health
- Debt / equity
- 0.11×
- Altman Z-score
- -13.83
- Piotroski F-score
- 4 of 9
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 19.53M USD | 14.29M USD | 12.74M USD | 13.27M USD | 12.63M USD |
| Cost of goods sold | 12.11M USD | 8.82M USD | 7.99M USD | 8.8M USD | 8.64M USD |
| Gross profit | 7.42M USD | 5.47M USD | 4.75M USD | 4.48M USD | 3.99M USD |
| Research and development | 2.27M USD | 1.81M USD | 1.87M USD | 207K USD | 125K USD |
| Selling, general, and administrative | 7.61M USD | 7.36M USD | 7.58M USD | 8.84M USD | 9.76M USD |
| Operating expenses | 9.88M USD | 9.18M USD | 9.45M USD | 9.05M USD | 9.88M USD |
| Interest income | — | — | — | 16K USD | — |
| Interest expense | — | — | — | — | 10K USD |
| Depreciation and amortization | 139K USD | 138K USD | 176K USD | 125K USD | 186K USD |
| Operating income | −2.46M USD | −3.71M USD | −4.7M USD | −4.57M USD | −5.89M USD |
| Net income | −3.18M USD | −3.46M USD | −4.84M USD | −5.15M USD | −5.09M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -231.61%
- 11 comparable reports
- Latest EPS result
- 0.02
- Estimate -0.3 · Beat by 106.67%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
SNOA news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Aug 30, 2024 | 1:20 | — | — |
Stock split | Jun 20, 2019 | 1:9 | — | — |
Stock split | Jun 27, 2016 | 1:5 | — | — |
Stock split | Apr 1, 2013 | 1:7 | — | — |
Effective Aug 30, 2024
1:20
Effective Jun 20, 2019
1:9
Effective Jun 27, 2016
1:5
Effective Apr 1, 2013
1:7
SNOA peers
ETFs holding SNOA
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research SNOAresearch.disclaimer










